<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NORFLOXACIN</span><br/>(nor-flox'a-sin)<br/><span class="topboxtradename">Chibroxin, </span><span class="topboxtradename">Noroxin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">quinolone antibiotic</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>400 mg tablets; 0.3% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>Potent broad-spectrum antibiotic activity. Alters structure of bacterial DNA gyrase, thus promoting double-stranded DNA breakage,
         interfering with synthesis of bacterial protein and blocking bacterial survival.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active against many bacterial urinary tract pathogens including: <i>Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae,</i> indole-positive <i>Proteus</i> sp., <i>Pseudomonas aeruginosa, Staphylococcus aureus,</i> group D <i>Streptococci, Neisseria gonorrhoeae,</i> and common GI pathogens (e.g., <i>Salmonella, Shigella</i>).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Complicated and uncomplicated urinary tract infection (UTI) caused by susceptible organisms. Conjunctivitis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Gonorrhea, gastroenteritis, and prevention of travelers' diarrhea.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Use in individual with known factors that predispose to seizures; history of hypersensitivity to norfloxacin and other quinolone
         antiinfectives; pregnancy (category C), lactation. Safety in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney function, adolescents if skeletal growth is complete.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Tract Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg b.i.d.<br/><br/><span class="indicationtitle">Conjunctivitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> 12 drops q.i.d.<br/><br/><span class="indicationtitle">Gonorrhea or Gonococcal Urethritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 800 mg once/d<br/><br/><span class="indicationtitle">Bacterial Gastroenteritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg q812h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 1 h before or 2 h after meals with a full glass of water.</li>
<li>Administer concomitant antacid at least 2 h after norfloxacin to prevent interference with absorption. Aluminum or magnesium
            ions in the antacid may bind to and form insoluble complexes with the quinolone in GI tract.
         </li>
<li>Store at 40° C (104° F) or less in tightly closed container. Do not freeze.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Musculoskeletal:</span> Joint swelling, cartilage erosion in weight-bearing joints, tendonitis. In immunosuppressed adult: acute ankle and hip pain
      followed by acute pain, tenderness, and swelling of tendon sheath of middle finger of both hands after 4 wk of therapy. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, lightheadedness, fatigue, drowsiness, somnolence, depression, insomnia, seizures, peripheral neuropathy. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> abdominal pain, diarrhea, vomiting, anorexia, dyspepsia, dysphagia, dry mouth, bitter taste, heartburn, flatulence, pruritus
      ani, increased serum AST, ALT, alkaline phosphatase. <span class="typehead">Hematologic:</span> Leukopenia, neutropenia. <span class="typehead">Urogenital:</span> With high doses: Crystalluria (not associated with renal toxicity), vulvar irritation. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause false positive on <span class="alt">opiate screening tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification"> antacids</span>, <b>iron,</b>
<b>sucralfate</b> decrease absorption; <b>nitrofurantoin</b> may antagonize antibacterial effects; may increase hypoprothrombinemic effects of <b>warfarin;</b> may cause slight increase in <b>theophylline</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 3040% absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span>  Renal parenchyma, gallbladder, liver, prostate; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine and feces. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Collect urine specimens for testing before initiating antibiotic.</li>
<li>Lab tests: Periodic WBC with differential, liver enzymes, and alkaline phosphatase, especially with prolonged use.</li>
<li>Report to the physician if patient is adequately hydrated, yet I&amp;O ratio and pattern changes are noted, or if condition does
            not improve within a few days. Dosage may need to be modified.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug at same times each day.</li>
<li>Take drug exactly as prescribed. Erratic dosing can encourage emergence of resistant bacteria; underdosing or premature discontinuation
            of treatment can cause return of UTI symptoms.
         </li>
<li>Keep fluid intake high (at least 25003000 mL/d if tolerated) to provide adequate urine output and hydration, important
            in the prevention of crystalluria (rare side effect).
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>